Diagenic Presents Test Data for Parkinson Disease at European IPA Meeting
News May 11, 2006
DiaGenic ASA has announced that it had presented a poster on discriminatory assays for Parkinson and Alzheimer’s diseases at the European Regional Meeting of the International Psychogeriatric Association in Lisbon.
The study employed a peripheral blood-based assay with a specific Alzheimer’s gene expression signature developed using DiaGenic’s patented method.
Researchers found that 19 out of 20 Parkinson-diagnosed patients could be discriminated from Alzheimer’s sufferers. Furthermore, a specific gene expression signature for Parkinson was also identified.
The study is part of a larger follow-on study validating DiaGenic’s Alzheimer’s gene expression assay on an ABI microarray platform, the results of which will be presented at the ICAD in Madrid in July.
"These findings showing that our blood-based gene expression assay approach can also be applied to Parkinson disease is extremely encouraging," said Anders Lonneborg, CEO, DiaGenic ASA.
"Alzheimer’s and Parkinson have different underlying pathologies, but overlapping clinical profiles as many PD patients will also develop dementia."
"Our goal is develop simple blood-based tests that will enable physicians to discriminate between patients at an early stage, since an increasing number of studies show that early therapeutic intervention can make a significant difference in improving quality of life."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.